Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 2 | 2023 | 86 | 0.870 |
Why?
|
| Tobacco Use Disorder | 2 | 2023 | 117 | 0.810 |
Why?
|
| Students, Medical | 1 | 2023 | 102 | 0.700 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 142 | 0.650 |
Why?
|
| Smoking | 2 | 2023 | 480 | 0.260 |
Why?
|
| Humans | 16 | 2023 | 29078 | 0.240 |
Why?
|
| Pennsylvania | 2 | 2023 | 11 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 130 | 0.230 |
Why?
|
| Texas | 2 | 2022 | 138 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 105 | 0.220 |
Why?
|
| Pelvic Floor | 2 | 2016 | 35 | 0.220 |
Why?
|
| Pandemics | 2 | 2023 | 206 | 0.210 |
Why?
|
| Curriculum | 2 | 2023 | 307 | 0.210 |
Why?
|
| Problem Solving | 1 | 2023 | 28 | 0.190 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 49 | 0.190 |
Why?
|
| Physicians | 1 | 2023 | 83 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 360 | 0.190 |
Why?
|
| Hydrocortisone | 1 | 2023 | 89 | 0.190 |
Why?
|
| Medically Uninsured | 1 | 2022 | 31 | 0.180 |
Why?
|
| Middle Aged | 7 | 2022 | 7458 | 0.180 |
Why?
|
| Aspirin | 1 | 2022 | 125 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 177 | 0.170 |
Why?
|
| Incidence | 1 | 2022 | 574 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2023 | 263 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 29 | 0.150 |
Why?
|
| Occupations | 1 | 2019 | 9 | 0.150 |
Why?
|
| Employment | 1 | 2019 | 49 | 0.140 |
Why?
|
| United States | 2 | 2022 | 2252 | 0.140 |
Why?
|
| Social Class | 1 | 2019 | 82 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 39 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 133 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 42 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2018 | 111 | 0.140 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 9 | 0.130 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 153 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2017 | 22 | 0.130 |
Why?
|
| Insurance, Health | 1 | 2017 | 51 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 285 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 481 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 44 | 0.120 |
Why?
|
| Pubic Bone | 1 | 2016 | 3 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 165 | 0.120 |
Why?
|
| Female | 10 | 2022 | 15740 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 348 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.110 |
Why?
|
| Endosonography | 1 | 2014 | 37 | 0.100 |
Why?
|
| Adult | 6 | 2022 | 8080 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 556 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2014 | 84 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 705 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2023 | 245 | 0.090 |
Why?
|
| Income | 2 | 2022 | 38 | 0.080 |
Why?
|
| Male | 6 | 2022 | 14049 | 0.080 |
Why?
|
| Aged | 4 | 2018 | 5627 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2020 | 2430 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 1286 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1009 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 119 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2022 | 46 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2022 | 47 | 0.050 |
Why?
|
| Young Adult | 2 | 2022 | 2855 | 0.050 |
Why?
|
| Obstetrics | 1 | 2022 | 57 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2651 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 185 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 191 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 30 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 312 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 226 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cotinine | 1 | 2019 | 46 | 0.040 |
Why?
|
| Smoke | 1 | 2019 | 37 | 0.040 |
Why?
|
| Saliva | 1 | 2019 | 96 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1015 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 109 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 67 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 196 | 0.040 |
Why?
|
| Pregnancy | 1 | 2022 | 1261 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 116 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 271 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 194 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 502 | 0.030 |
Why?
|
| Smokers | 1 | 2019 | 129 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 253 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2019 | 103 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 108 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 126 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 612 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 171 | 0.030 |
Why?
|
| Diet | 1 | 2018 | 241 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 288 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 433 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 328 | 0.030 |
Why?
|
| Colposcopy | 1 | 2016 | 63 | 0.030 |
Why?
|
| Parity | 1 | 2016 | 50 | 0.030 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2016 | 24 | 0.030 |
Why?
|
| Tobacco Products | 1 | 2019 | 209 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 827 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 3233 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 244 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 815 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1360 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 6 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 108 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1672 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 1619 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 525 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1482 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 788 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 482 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 882 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 10756 | 0.010 |
Why?
|